Back to top
more

VERADIGM INC (MDRX)

(Delayed Data from OTC)

$7.96 USD

7.96
249,847

+0.01 (0.13%)

Updated Apr 26, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Technology Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Masimo's (MASI) Patient Monitoring Devices Favored by New Study

by Zacks Equity Research

Masimo's (MASI) patient monitoring devices continue to aid researchers in their assessment of different ventilatory strategies for brain oxygenation during thoracoscopic surgery.

Strength Seen in Veradigm (MDRX): Can Its 5.0% Jump Turn into More Strength?

by Zacks Equity Research

Veradigm (MDRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Here's Why You Should Retain Veradigm (MDRX) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Veradigm (MDRX) owing to its strategic alliances.

3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

Allscripts (MDRX) Q3 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.

AllScripts Healthcare (MDRX) Q3 Earnings Top Estimates

by Zacks Equity Research

AllScripts (MDRX) delivered earnings and revenue surprises of 21.05% and 0.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Hims & Hers Health, Inc. (HIMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate AllScripts Healthcare (MDRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

MDRX vs. OMCL: Which Stock Is the Better Value Option?

by Zacks Equity Research

MDRX vs. OMCL: Which Stock Is the Better Value Option?

NextGen's (NXGN) Enterprise Adopted by Oak Orchard Health

by Zacks Equity Research

NextGen's (NXGN) EHR and PM solution is expected to aid Oak Orchard Health in improving its workflow.

Here's Why You Should Hold on to Allscripts (MDRX) Stock Now

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

MDRX vs. OMCL: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

MDRX vs. OMCL: Which Stock Is the Better Value Option?

Can AllScripts (MDRX) Climb 27% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in AllScripts (MDRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Allscripts (MDRX) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Allscripts' (MDRX) robust Q2 results demonstrate strength in both segments.

AllScripts Healthcare (MDRX) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AllScripts (MDRX) delivered earnings and revenue surprises of 12.50% and 2.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AllScripts Healthcare (MDRX) Q2 Earnings Expected to Decline

by Zacks Equity Research

AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

Olink Holding AB publ Sponsored ADR (OLK) Surges 7.3%: Is This an Indication of Further Gains?

by Zacks Equity Research

Olink Holding AB publ Sponsored ADR (OLK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Allscripts' (MDRX) Stock Falls 8.8% Post Q1 Earnings Miss

by Zacks Equity Research

Allscripts' (MDRX) robust Q1 results demonstrate strength in both segments.

    AllScripts Healthcare (MDRX) Q1 Earnings and Revenues Lag Estimates

    by Zacks Equity Research

    AllScripts (MDRX) delivered earnings and revenue surprises of -35% and 61.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Here's Why You Should Retain Allscripts (MDRX) Stock For Now

    by Zacks Equity Research

    Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.

    Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio

    by Zacks Equity Research

    Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee and regulatory approvals.

    Masimo (MASI) Announces Favorable Study Results on SpHb

    by Zacks Equity Research

    Masimo's (MASI) SpHb is likely to enhance perioperative transfusion management and post-operative patient outcomes on pediatric patients.

    Are You Looking for a Top Momentum Pick? Why AllScripts Healthcare (MDRX) is a Great Choice

    by Zacks Equity Research

    Does AllScripts Healthcare (MDRX) have what it takes to be a top stock pick for momentum investors? Let's find out.